0002
290310224
911 Áàäÿãà ãåëü ï/ñèíÿê/óøèá 100 ìë
Òâèíñ ÒÝÊ ÇÀÎ
Ðîññèÿ
76fe1c3ff1490462aaf21d2776624112
4607010243104
Àãàðèêóñ ãðèá 50ã Ìàðèñëàâíà ÐÔ
ÐÔ
dad96548df5b083843c3166da3eb66f3
7930057391949
Àåâèò êàïñ N 30 ÐÁ ÌÈÊ
Ìèíñêèíòåðêàïñ / ÐÁ
ÐÁ
a1fef2186770a5bffe4c1660eceb2f36
4810046008320
Àçàðãà êàï ãë 10ìã+5ìã/1ìë 5 ìë
Àëêîí Ëàáîðàòîðèç
Áåëüãèÿ
143b9291b82974788ba3f342bcc4808c
5413895021466
Àêàíòîïàíàêñ 25 ãð Ôèòî-Àïòåêàðü ÐÔ
9f89879b5eef9c6435c43da150410123
Àêâàñîë ñïðåé íàçàëüí 30 ìë ÐÁ Ðóáèêîí
Ðóáèêîí ÎÎÎ
ac38b6111ad64d750a60083c65eb052d
4810243005931
Àìëîòåíçèí êàïñ 8ìã/10ìã N 30 ÐÁ Ëåêôàðì
Ëåêôàðì
9420897950a64ea0fcc13401457506e4
4812608003903
Àììèàêà ð-ð 10% 100 ìë ÐÔ
ÐÓÑÊÅÐÍ ÎÎÎ
b181f9627066831e2cb5eaa5ec910fb0
4640026210449
Àìîêñèêëàâ 2Õ òàá 875ìã/125ìã N 14
Ëåê
Ñëîâåíèÿ
f88dc58c8e77230dffd89a210b7a1d9d
3838957006656
Àìîêñèöèëëèí òàá ï/î  500 ìã N 20 ÐÁ Ôàðìòåõ
Ôàðìòåõíîëîãèÿ
646f9ea3e626c4f3dc3145089edbda4b
4810183013881
Àìîêñèöèëëèí òàá ï/î 1000 ìã N 12 ÐÁ Ôàðìòåõ
a665317ee6b23e5ffcf4eda638ccc273
4810183013911
Àíãèîâèò ìàãíèé êàïñ N 60 Áàä
Àëòàéâèòàìèíû
8af259bff3f3834905160fac9ea5c091
4603679007767
Àíçèáåë ïàñò N 20
Íîáåëü Èëà÷
Òóðöèÿ
2a27e63727b5450f3eddb96bcd3392a3
8699540110120
Àíçèáåë ïàñò ðàññàñ N 20 ìåä-ëèìîí
a5c73fd7bb806039f2cd20aab1464164
8699540110038
Àíèñ ïëîäû 50 ã Ìàðèñëàâíà ÐÔ
7e54cca4fffa074719773ddef6ef8660
7930047479930
Àðòåëàê Âñïëåñê ð-ð îôòàëüìîëîã ôë 10 ìë
Ä-ð Ãåðõàðä Ìàíí
Ãåðìàíèÿ
980ccdb121d042ce268c30894cf1a3a2
4029835000159
Àðòåëàê ãåëü îôòàëüì íî÷íîé 10 ã
15462bc060ffe416159769c78de11c33
4030571005209
Àðòîêñàí ïîð ä/ïðèã ð-ðà 20 ìã N 3
Ðîòòàôàðì
Âåëèêîáðèòàíèÿ
5d64fa862fe5b969492bf9ba5fc6b5f5
6221032311115
ÀÑÄ 2 ñâå÷è N 10 Ôèòî-Àïòåêàðü ÐÔ
babc4c69f123b841eb222843260fef25
Àñêîðáèí ê-òà ñ ãëþêîçîé òàá 3,0ã N10 á/âêóñà ÐÁ Áàä
ÁèîÇäðàâèò ÎÎÎ, Áåëàðóñü
e2d8724279311af5e4057baa67254126
4810621001906
Àñêîðáèí ê-òà+ãëþêîç òàá 50 ìã/438 ìã N 10 ÐÁ Ýêçîí
Ýêçîí
1e4ae22a2f19875c7d60ddde090b728c
4810155002066
Àñïèêàðä òàá ï/î 75 ìã N 30 ÐÁ Áîðèñ
Áîðèñîâ.ç-ä ìåä.ïðåï.
c5294ad88f8a2f4d45ffa1d5f6b7a127
4810201014890
Àñïèðèí+Ñ òàá øèï 400ìã/240ìã N 10
Áàéåð Êîíñüþìåð
5f94576a262d398d2ee9849ba7c28772
4250369505104
Àñòðàãàë íàñòîéêà 250 ã Ôèòî-Àïòåêàðü ÐÔ
c875a9f50eb620fa7448ff5971ac3c8d
Àöåêëîôåíàê êàïñ 100 ìã N 60 ÐÁ ÌÈÊ
a423966818cb788bef98cf2dfaed9047
4810046006746
Áàðáàðèñ êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
a581c97537d546f5a5b7e5bffc5cba83
7930047475130
Áàðõàò àìóðñêèé ÿãîäû 50 ã Ìàðèñëàâíà ÐÔ
6e4e1ad320d39947ee0452dba74831e7
7930057391260
Áåíçèëáåíçîàò ìàçü 20% 30 ã ÐÁ Ôàðìòåõ
de8a616d9405c128355374f73aeedefa
4810183005152
Áåðåçà ëèñò 50 ã Ìàðèñëàâíà ÐÔ
41ee9cc56201b5ebe7b317a009568c29
7930047475154
Áåññìåðòíèê ïåñ÷àíûé öâåòêè 50ã Ìàðèñëàâíà ÐÁ
2147064b754f6188c267339d6a7eea5c
7930047475178
Áåòàäèí ìàçü 10% 20 ã
Ýãèñ
Âåíãðèÿ
3697fad47d5327ae319dab0a5b60eec9
5995327146287
Áèíò ñòåð 10 ñì õ 500 ñì ÐÁ Ãàëòåÿôàðì
ÃàëòåÿÔàðì
8fc3b9c1828227e8b1524a38969d421f
4812635000777
Áèíò ýëàñò  8 ñì õ 250 ñì âÿçàí ÐÁ
Áåëïà-ìåä
dd16c4f3033ea71d8c10f15ac6fdb7de
4810844001202
Áèíò ýëàñò 10 ñì õ 60 ñì âÿçàí   ÐÁ
8abce91486c6c3c9cc1aa4cc26434c23
4810844001240
Áèôèöèí Ôîðòå êàïñ N 10 Áàä
Êâàíòóì Ñîëþøíñ Ãðóï Ëòä, Âåëèêîáðèòàíèÿ
f57ab8e1c4289b2330855f739cf8bd0f
5060391652290
Áëåìàðåí òàá øèï. N 80
Esparma GmbH, Ãåðìàíèÿ/Laboratorios Medicamentos I
f611f4edb73bf1141d1b858f49733bf6
4029438280019
Áîëèãîëîâà ìàçü 100 ãð Ôèòî-Àïòåêàðü ÐÔ
45b9cb0c71317cb6be9ac7533d213576
Áîëèãîëîâà ìàçü 30 ìë Ôèòî-Àïòåêàðü ÐÔ
a24a8a111fb2eb7f00d73edf3d7f5be9
Áîëèãîëîâà ìàçü 40 ã Ìàðèñëàâíà ÐÔ
fb3542302001249ddf49e84b4e91dea9
7930047474539
Áîëèãîëîâà ìàñëî òàìïîíû 100 ìë Ìàðèñëàâíà ÐÔ
aa6806ebb020dff37967c111f94e1813
7930047473938
Áîëèãîëîâà íàñòîéêà 100 ìë Àëòàé ÐÔ
c35c4690b10410ee65a1d6d4728882e8
Áîëèãîëîâà íàñòîéêà 200 ìë Àëòàé ÐÔ
95de83e9bb931dbb3b3bdad17b47e941
Áîëèãîëîâà ñîê 50 ìë Ôèòî-Àïòåêàðü ÐÔ
81f1ab6c63194bbfff4069a6476ce58f
Áîðèâèò òàá ï/î N 30 ÐÁ Áîðèñîâ
2850b56311a01e6831eff1e7e1660b22
4810201018782
Áîðíàÿ ê-òà ð-ð 3% 25 ìë ÐÁ Áîðèñ
0b8eec0c2bc79ae89b51b4fff8a2979a
4810201020525
Áîðîâàÿ ìàòêà íàñòîéêà 100 ã Ôèòî-Àïòåêàðü ÐÔ
d134df194c85028c802683ea8a9c30cf
Áîðîâàÿ ìàòêà íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
b655529ec1f4b042c4c2bdb02ace2e4b
Áîÿðûøíèê öâåò+ëèñò, 50 ã Ôèòî-Àïòåêàðü ÐÔ
5c2a454fc95681d590915b608fda04bd
Áîÿðûøíèêà êîâàâîêðàñíîãî öâåòû 50 ã Áàä
Êîìïàíèÿ ÕÎÐÑÒ
9ce5b5fb8f43101f3a3b1a2b503b5c79
4680002555843
Áîÿðûøíèêà öâåòû êðîâàâî-êðàñíîãî 50 ã Ìàðèñëàâíà ÐÔ
33e5a3c7a4922ac7b4bab4a29d757994
7930047475215
Áðîíõîçàâð ëåäåíöû ä/äåò 10ã N 6 ÁÀÄ Ä-ð Òàéñ
ÏÒÔ ÅÂÀ ÀÎ
Ïîëüøà
ba2814a344aaa1f18a7a7e7dfaba7ffb
4016369662915
Áóçèíû öâåòû 25 ã Ôèòî-Àïòåêàðü ÐÔ
998868abc43533867787856647a8b5ee
Áóçèíû ÷åðíîé ïëîäû 50 ã Ìàðèñëàâíà
8c75a4a98e836bbc63180a7f058c49ae
7930047478537
Áóçèíû ÷åðíîé öâåò 50 ã Ìàðèñëàâíà ÐÔ
7fa6d8ff24957a7ab965c2f31da12800
7930047475239
Âàëåðèàíà êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
73888bd625c6cb782040bc8b964ccae6
7930047475253
Âàëåðèàíû òàá 200 ìã N 50 ÐÁ ÁÌÏ
Áåëìåäïðåïàðàòû
e084e2e8d0c2b1c2f5c6fbdb8019dd80
4810133004136
Âàëåðèàíû òàá ï/î 200 ìã N 20 ÐÁ ÁÌÏ
900990cb5103bf2f7dca8477dd579475
4810133007311
Âàñèëüêà ñèíåãî ãèäðîëàò ñïðåé 100ìë Ìàðèñëàâíà ÐÔ
68d86df85ccb8a0420ac90102054b38f
7930047470647
Âàòà ñòåð 100 ã ÐÁ Ìåäâàòôàðì
Ìåäâàòôàðì
822f162dcceadfb388e36b99aa486aad
4813246000118
Âåëàêñèí êàïñ 75 ìã N 28
0d588838b1c76b16fe2eb9b09038daaa
5995327153032
ÂåíÀêòèâ Ñîñóäèñòûå çâåçäî÷êè ãåëü-áàëüç ä/íîã 125ìë ÐÔ
Êîðîëåâ Ôàðì
62b6d45a20fd8c68ba523e5a6f8b5379
4607011669361
Âèíîãðàä êðàñíûé ëèñò 50 ã Ìàðèñëàâíà ÐÔ
2dceccadcdf3109a99e630a51162ff6a
7930047475291
Âèïðîñàë Â ìàçü 30 ã
Òàëëèíñêèé ÔÇ/Ãðèíäåêñ ÀÎ,Ýñòîíèÿ
Ýñòîíèÿ
84843e32190c0e065e5d942767278690
4750232013175
Âèñ Ãëèê Íåî êàïëè ãëàçíûå 10 ìë
OPKO HEALTH SPAIN, S.L.U.
Èñïàíèÿ
a9caac760f1a583f0a25f7a91ddf252a
8414042005251
Âèò Å êàïñ 400 ìã N 30 ÐÁ ÌÈÊ
a0ea23606f0b979c3ef352707401aa0f
4810046004124
Âèòðóì ÈììóíÀêòèâ òàá øèï 3.8ã N 20 Áàä ÐÁ Ìàëêóò
Ìàëêóò
c231112944a44d9c04f62d6d1c1c5c8e
4810910005264
Âîäà ìèí Áîðæîìè 0.5 ë Ïýò
Àèäèåñ Áîðæîìè, Ãðóçèÿ
Ãðóçèÿ
af7ac10907688870198f455a2b688bce
4860019001353
Âîäà ïèò ïðèð í/ãàç Ñâÿòîé Èñòî÷íèê 0.5 ë ïýò
ÎÎÎ ÇÀÂÎÄ ÑÂßÒÎÉ ÈÑÒÎ×ÍÈÊ
c2c824d41d3746243ab3f2d28b087306
4603934000786
ÃåëåíÂåí Ôëåáîãåëü ä/íîã ñ äâîéíûì ýêñòð ëèñòüåâ âèíîãðàäà 125 ìë
bae02f5b79c819b608b5f954e1076750
4607011668845
Ãåëü-ñìàçêà Êîíòåêñ  30 ðîìàíòèê êëóáíèêà
ÀëüòåðÔàðìàöèÿ
×åøñêàÿ Ðåñïóáëèêà
94adec3214f5e9a0bef873d68a6b055d
5060040304532
Ãåìàòîãåí Ãåìàòîãåíêè â áåë ãë 10ã N5 ÁÀÄ ÐÁ
ÔÀÐÌËÝÍÄ ÁÈÎ ÎÎÎ
607a8a1e4664297cb0ee8adea852e90f
4814540000743
Ãåìàòîãåí ñ àðàõèñîì 40 ã ÐÁ Áàä Ýêçîí
d3cb36ab468498a9588c195b39cc32d3
4810155001861
Ãåíòàìèöèíîâàÿ ìàçü 0.1% 25 ã ÐÁ ÁÌÏ
4f4faf7a63343fe0cfe379f9cb916d54
4810133006826
Ãåíòîñ êàïëè 20 ìë
Ðèõàðä Áèòòíåð
Àâñòðèÿ
6aeaa354eee4ab7b972a54db46aea98a
9005441232035
Ãåïàòðèí êàïñ 0.33 ã N 30 Áàä Ýâàëàð
Ýâàëàð
5969f25e962d48f35a46b401fcb2e707
4602242002185
Ãåðáèîí ñèð ïåðâîöâåòà/òèìüíà 150 ìë
ÊÐÊÀ
90e494f73a3a7e56a19a53feb9e782c8
3838989702779
Ãèäðîêîðòèçîí ãë ìàçü 0.5% 3 ã ÐÔ
Òàòõèìôàðìïðåïàðàòû
f145edf515aaeed1c4939ffa125b6e83
4604060002484
Ãëèíà  100 ã Ðîçîâàÿ Ìàðèñëàâíà ÐÔ
de8de81488c0e1cf982c496236a9613c
7930057392106
Ãëþêîçà òàá æåâ 2 ã N 15 ÐÁ âêóñ êëóáíèêè Ýêçîí
dc62f97a1f157459bcdb664f85689c42
4810155001526
Ãîëþêà ìàçü îò ïñîðèàçà 300 ãð Ôèòî-Àïòåêàðü ÐÔ
a9be85acdb827df6d7ac977d79c81b47
Ãîðåö ïî÷å÷óéíûé 50 ã Áàä Õîðñò
71c46bde9afdda6f46f0fc3c22ba6bf8
4670018483315
Ãðèá Âåñåëêà íàñòîéêà 100 ìë
862eb6f40f9d3d47ee08359800c031e9
Ãðèá Ëèñè÷êè íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
16f08dfb3996280daf25a7a7b942bfc1
Äåãîòü Áåðåçîâûé 50 ìë Ìàðèñëàâíà ÐÔ
446e26c5300959ac1f7c3c7c51ec1fca
7930057391222
Äåãòÿðíàÿ ìàçü 40 ã Ìàðèñëàâíà ÐÔ
73222ac09ced80d7d2e203b27ba4b527
7930047474652
Äåêñàëãèí ð-ð ä/èíô 25ìã/ìë 2 ìë N 5
Ìåíàðèíè
Èòàëèÿ
6189e9a5a29ffc6ab2955d6b72b72e9d
4013054008027
Äåêñïàíòåí ìàçü 50ìã/1ã 30 ã ÐÁ Ôàðìòåõ
fd93d31a8d7b7d8206bd39a862122294
4810183008450
Äèëàñèäîì òàá 4 ìã N 30
Pharmaceutical Works Polpharma S.A, Ïîëü
1a460d99a9b0e5b076e956d3a69229a2
5900257008123
Äèîñêîðåÿ êàâêàçêàÿ êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
9170ab793a4410ce67e8953db7b912d3
7930047475406
Äèîñêîðåÿ íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
eacf5992c39f68beb9a4d4fa63c58d7c
Äîïïåëüãåðö àêò Âèò-ìèí ê-ñ 50+ 1.765 ã N 30 Áàä
Êâàéññåð Ôàðìà
20e3e99bdb92e92e353a234dab3c97e3
4009932559187
Äóðíèøíèê íàñòîéêà (Àäåíîìà ñòîï) 100 ìë Ôèòî-Àïòåêàðü ÐÔ
ebdb50551d92b188cc65de85cd14e14a
Äóøèöà òðàâà 50 ã Ìàðèñëàâíà ÐÔ
1cd064753b1fab2cbb355d4a8b4cb496
7930047475451
Äóøèöà òðàâà 50 ã Ôèòî-Àïòåêàðü ÐÔ
c305fe8ca1b15abf90bbc98f2a610989
Æåíüøåíü êîðåíü 20 ã Ìàðèñëàâíà ÐÔ
9eee96ca29a320d3f4ba881b9c68207c
7930057391635
Æèâèöà êåäðîâàÿ ñìîëà 50 ã Ìàðèñëàâíà ÐÔ
3dc54d81c73db2468a145c6a0f7d2cc3
7930057394780
Çâåðîáîÿ òðàâà 50 ã Ìàðèñëàâíà ÐÔ
1ce385f7cbd13d6327a59e4aafb3e31a
7930047475505
Çîëîòàÿ ðîçãà òðàâà /çîëîòàðíèê/ 50 ã Ìàðèñëàâíà ÐÔ
86c49dfc27e008f4316804fff34e6d9a
7930047475543
Çîëîòîé êîðåíü (ðîäèîëà ðîçîâàÿ) íàñòîéêà 250 ãð Ôèòî-Àïòåêàðü ÐÔ
074b258a7e8545df94c1fd3aae32ff4c
Çîëîòîòûñÿ÷íèêà òðàâà ôèòî÷àé ô/ï 1.5ã N 20 Áàä
f0ac1284ae4ad725030cd9c4a2ac8a5c
4680002552873
Èáóïðîôåí Ìàêñ òàá ï/î 400 ìã N 20 ÐÁ Áîðèñ
0804775ed1b7f86822eebf171cdab11e
4810201018454
Èáóôåí ãåëü ä/íàð ïðèì 10% 50 ã
Pharmaceutical Works POLPHARMA S.A. Medana Branch
1de4c49a4be1df0cf0cdb406e8d7b12b
5907529461235
Èâàí-÷àé êëàññè÷åñêèé ô/ï 2.0 N30 Ìàðèñëàâíà ÐÔ
eaabd7a987e48d62cf5b82ebdf001e45
7930057392632
Èâàí-÷àé ñ îáëåïèõîé ô/ï 2.0 N30 Ìàðèñëàâíà ÐÔ
749ffb680970a3b22cab5ba02d13e672
Èâàí-÷àé ñ ðîçìàðèí/âèøíåé ô/ï 2.0 N30 Ìàðèñëàâíà ÐÔ
28767d9a9bfb08248a9867211a481115
7930057392731
Èíäàïàìèä òàá 2.5 ìã N 30 ÐÁ Ôàðìëýíä
Ôàðìëýíä
09514046e4e0ec6dcb6214eb859e5747
4810368009470
Èíäîë Óëüòðà òàá 500 ìã N 60 Áàä
ÎÎÎ Ôàðìãðóïï
2612b451e44c75a740884f2e87b7a760
4660200080354
Èíäîìåòàöèí ìàçü 10% 40 ã
Ñîôàðìà
Áîëãàðèÿ
33853655c787cdd6baeacc8a03f2c424
3800010650700
Éîäîìàðèí òàá 200 ìêã N 100
Áåðëèí Õåìè ÀÃ,Ãåðìà
Ëèòâà
d014ab7b008183ac53f0fe51700623cd
4013054004654
Êàáåðëèí òàá 0.5 ìã N 2 ÐÁ Áîðèñ
ÐÁÁîðèñîâñêèé ÇÌÏ/Sun Pharmaceutical Industries Ltd, Èíäèÿ
09acc64386492c4e824551b7110a7a33
4810201019406
Êàêàî ïîðîøîê ñûðîé (îðãàíèê) 100 ã Ìàðèñëàâíà ÐÔ
20c949a5945cdc2ab13ff9df6dc30c6f
7930047479978
Êàëãàí (ëàï÷àòêà ïðÿìîñòîÿ÷àÿ) êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
17d702feceeeb000db18eb5b43066614
7930047475604
Êàëãàí (ëàï÷àòêà ïðÿìîñòîÿ÷àÿ) íàñòîéêà 250 ã Ôèòî-Àïòåêàðü ÐÔ
483bd9ec58a32a0c5a62da3e0c8798eb
Êàëåíäóëà öâåòêè 50 ã Ìàðèñëàâíà
90f0039bae4c0b28be562afed23f3c21
7930047475611
Êàëåíäóëû ìàçü 25 ã òóá ÐÁ Áîðèñ
8b7f7dddcc3fe1c306edc40ef8f81425
4810201004228
Êàðâèäèë òàá 25 ìã N 28
Ãðèíäåêñ
Ëàòâèÿ
016219faa4a1e8026acdb7b9556f5a97
4750232007051
Êàøòàí êîíñêèé ìàñëî 100 ã Ìàðèñëàâíà ÐÔ
a731e3c45b9fa94a5975cf036859b218
7930047470197
Êàøòàí êîíñêèé öâåòû 50 ã Ìàðèñëàâíà ÐÔ
0887996a7df4960e91c19461acb88d10
7930047475642
Êàøòàí öâåòû ãèäðîëàò 100 ìë êðûøêà Ìàðèñëàâíà ÐÔ
e22e5f53d9e186694566af000311ea56
7930047470708
Êåäðîâîå ìàñëî 100% íåðàô 100 ìë Ìàðèñëàâíà ÐÔ
55c76dd034274bfc9427a07ede8752f9
7930047470616
Êåòèëåïò òàá ï/î 25 ìã N 30
42482e89023b6b16cc317fe124725ee1
5995327150383
Êåòîðîëàê-ËÔ òàá 10 ìã N 20 ÐÁ Ëåêôàðì
229223b132e0ac471efed3a07fd4183c
4812608011366
Êèïðåé óçêîëèñòíûé òðàâà 50 ã Ìàðèñëàâíà ÐÔ
4237fc8349ecd805b4c3488d4b5d2d73
-
Êèñåëü õîðîøàÿ ïàìÿòü 5ïàê ïî 20ã Ëåîâèò ÐÔ
Ëåîâèò íóòðèî ÎÎÎ,Ðî
d7779a1d000c78bc9eca6a0cd383bb65
4650070112460
Êèñëîòà îëåèíîâàÿ 100 ã Ìàðèñëàâíà ÐÔ
6efcb0c91a4cc0cb5613abd0c8170542
7930047479923
Êî-Àìëåññà òàá 8ìã/ 5ìã/2.5ìã N 30
2618a8e50dcd5493886d3bd800f8847c
3838989633066
Êî-Âàëîäèï òàá ï/î 5ìã/160ìã/12,5ìã N 30
ÊÐÊÀ-ÐÓÑ ÎÎÎ
8f1d430f8d9a71837624b56a46c6579f
3838989705916
Êîìïëèâèò òàá N60 ÁÀÄ ÐÔ
Ôàðìñòàíäàðò-ÓôàÂèòà
41be7d4db2fb33e66eada72b3d65ca2c
4601808015249
Êîïûòåíü åâðîïåéñêèé êîðåíü 50 ìë Ìàðèñëàâíà ÐÔ
96ab1a531747a60d1d9597a7d0d57876
7930047475680
Êðàïèâû êîðåíü 25 ã Ôèòî-Àïòåêàðü ÐÔ
2804d03626ddaa6804f495847aaf4158
Êðàïèâû ñîê 100 ìë Ôèòî-Àïòåêàðü ÐÔ
ad2bf7060444935d434124f4b709b594
Êðàñíàÿ ùåòêà êîðåíü äð 50 ã Ìàðèñëàâíà ÐÔ
1c3550d952c849b1c8de07915bb75856
7930047475710
Êðàñíàÿ ùåòêà íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
169aea3a67a72021bada144cc0d460d0
Êóêîëüíèê ëåêàðñòâåííûé êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
25c0e7f8d1b687dd78de8876b1e1822d
7930047475765
Ëàï÷àòêà áåëàÿ íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
b5796436f784b30154b40b49ba7ee9d7
Ëåâçåÿ /ìàðàëüåãî êîðíÿ/ 250 ìë Ôèòî-Àïòåêàðü ÐÔ
c06ad849885df682960640816c6c3ba8
Ëåñïåäåöà êîïåå÷íèêîâàÿ òðàâà 50 ã Ìàðèñëàâíà ÐÔ
84f53e543099d00ba0d835569d203d67
7930047475864
Ëèçèíîïðèë òàá 10 ìã N 30 ÐÁ Ôàðìë
49eb9a6aadb14589ffd1f9849d326434
4810368013088
Ëèçèíîïðèë òàá 10 ìã N 60 ÐÁ Ôàðìë
e2b72ba0afe3d8142e7690d5de6ff79d
4810368013095
Ëèìîííèê ñåìåíà íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
7c98d175cf2af5fe6f4eb25994f932ea
Ëèïðèìàð òàá 10 ìã N 30
Ïôàéçåð Ôàðì. ËËÑ,ÑØÀ/Ïôàéç. Ìàíóô.Äîé÷ë.ÃìáÕ, Ãåð
ÑØÀ
233977c28f918067403d8cc41857e310
5413973261319
Ëîçàðòàí Ïëþñ òàá  50ìã/12.5ìã N 30 ÐÁ Ëåêôàðì
c1a31f60711021e673c0a23e88555b00
4812608006638
Ëîêñèäîë-ÐÅÁ òàá 15ìã N10 ÐÁ
Âîðëä Ìåäèöèí
4bd2c7e0624d0495fa13da3bf5d61094
4813721001593
Ëîïóõà êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
60aed3ca3daf965c3116cace20f23b86
7930047475901
Ëîðèñòà H òàá ï/î 50ìã/12.5ìã N 30
KRKA ä.ä., Ñëîâåíèÿ
c78707bcdff9a7c936aff0462146c90a
3838989619411
Ëîðñåïò òàá ä/ðàññ 1.5 ìã N 20 àïåëüñèí ÐÁ Ðóáèê
6713df588752b7277beccccd1c0bd884
4810243003906
Ëüíà ñåìÿ 200 ã ÐÁ Áèîòåñò
Áèîòåñò
441696cbbec901f40d8e81497ae38a98
4810363001257
Ëüíÿíêè ìàçü 40 ã Ìàðèñëàâíà ÐÔ
c92b3191853d39031ca41c93ca46863e
7930047474553
Ëþòåèí 100% êàïñ N 60 Áàä
ÐåàëÊàïñ
68a097ed17ff6b7bbe8f1f837ea3627a
4607136740433
Ìàãâèò êàïñ N 50 ÐÁ ÌÈÊ
2eaca676d842cccc8335a23962182939
4810046004735
Ìàãíåôàð Â6 äð 500ìã/5ìã N 60
Áèîôàðì Ñ.À.
2f7c00dfcb900185ef2053e46a35a89f
5907695211030
Ìàãíèé-Äèàñïîðàë 300 ãðàí â ïàê 5ã N 20
Protina GmbH,Ãåðìàíèÿ
1dc39f6db9d29868e0b52b777d1279f9
4260124360176
Ìàêëþðû ìàñëî 100 ìë Ìàðèñëàâíà ÐÔ
b6254b9243129d0d121c4385a135d061
7930047470227
Ìàðåíà êðàñèë ÷àé ô/ï 1.5ã N20 Áàä ÐÔ Õîðñò
ace3e8ed0dd51f19bad282a41b183a31
4680002555034
Ìàðåíà êðàñèëüíàÿ 25 ã Ôèòî-Àïòåêàðü ÐÔ
ae8a363f56c246a0415d90106dfab0cc
Ìàðåíà êðàñèëüíàÿ êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
f679a67dff50da57c70e2fbb300f0126
7930047475949
Ìàñëî Êàñòîðîâîå 100 ìë êîñìåò Ìàðèñëàâíà
984de890526504c041dada9075096446
7930047470364
Ìåíîâàçèí ð-ð 40 ìë ä/íàðóæí ïðèì ÐÁ Áîðèñîâ
67007bbe1638cb58a5f907cc246dad58
4810201018737
Ìèäèàíà òàá ï/î 3ìã/0,03ìã N 21
Ãåäåîí Ðèõòåð
976464ebdd37b4e41f25229ca8617780
5997001362747
Ìèäîêàëì àìï. 10% 1 ìë N 5
6dae45b51677d3de318d9c391c8c1dd6
5997001391228
Ìîêñîíèäèí òàá ï/î 0.4 ìã N 30 ÐÁ Ëåêôàðì
2a4c6846c0d86f96fab3dd3e692e494c
4812608003538
Ìîëî÷àé Ïàëëàñà êîðåíü 10 ã Ôèòî-Àïòåêàðü ÐÔ
a07ed263573f913704c639797d5894f2
Ìîëî÷àé Ïàëëàñà êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
14ddc85ec74bfaa4efe0009348adf903
7930047476014
Ìîëî÷àé Ïàëëàñà íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
8411a4e5de8093ce34771c271513a049
Ìîëî÷àÿ Ïàëëàñà ìàçü 40 ã Ìàðèñëàâíà ÐÔ
c4746d578e6bb39bb2d10cbd590f29bd
7930047474577
Ìîðèñ ñïðåé íàç äîç 50ìêã/äîçà 140 äîç
6aaa3101c5b92e2f8fb8ea05792b1d85
3838957079490
Ìîðîçíèê â êàïñóëàõ N200 Ôèòî-Àïòåêàðü ÐÔ
1dd55c67222fcfd9f462fd1cfeb141aa
Ìîðîçíèê êàâêàçêèé êîðåíü ìîëîòûé+ìåðíàÿ ëîæêà 45 ã Ìàðèñëàâíà ÐÔ
9df571ad5ff9e4b321e994578fad4648
7930057394292
Ìîðîçíèê êàâêàçêèé êîðåíü ìîëîòûé+ìåðíàÿ ëîæêà 90 ã Ìàðèñëàâíà ÐÔ
43ddb296b650bdb6cf41a40061d09898
7930047476038
Ìóìèå àëòàéñê Áàëüçàì ãîð òàá 200ìã N 60 Áàä
Ôàðì-Ïðîäóêò
69251484fe8dce590f73937f3f84b41b
4607117341765
Ìóõîìîð ìàñëî 50 ìë Ôèòî-Àïòåêàðü ÐÔ
27002e8ded2e75e3fd36349417e23efe
Ìóõîìîðà êðàñíîãî íàñòîéêà 100 ìë Ôèòî-Àïòåêàðü ÐÔ
15ce8c50eb6a1936f5bea5af5a9a4875
Ìóõîìîðà êðàñíîãî íàñòîéêà 50 ìë Ôèòî-Àïòåêàðü ÐÔ
3e749ea10c3791772e94ff066a6efc3c
Íàéñóëèä ãåëü ä/íàðóæí ïðèìåí 10 ìã/1ã 30 ã ÐÁ Ôàðìòåõ
5a82190b1a66adafaeec04e6d9e8d373
4810183005381
Íàêëîôåí àìï. 75 ìã/3 ìë N 5
72c07281df660b6684546ec0a7caf44f
3838989565503
Íàôàçîëèí êàïëè íàç 0.1% 30 ìë ÐÁ Ðóáèêîí
4523c5ca7fdcdb9c97a789ddfa479fb7
4810243007294
Íåéðîìèäèí àìï 1.5% 1 ìë N 10
Îëàéíôàðì
e3995e318cbd2a40b3782fa5a66d62dd
4750258315444
Íèìåñóëèä òàá 100 ìã N 20 ÐÁ Ôàðìë
b5adf30436154c41d955bae978273a6f
4810368009425
Íî-øïà òàá 40 ìã N 100
ÕÈÍÎÈÍ Çàâîä Ôàðìàöåâòè÷åñêèõ è Õèìè÷åñêèõ ïðîäóêò
5ee32b1e8d5942823f0d42346bbfcb30
5997086103280
Íî-øïà òàá 40 ìã N 24
Õèíîèí
4b2fa70aebc3dcc3d69e5ee550497406
3582910065449
Íîçàêàð Ýêñòðà óâëàæ ñïð 0.05% 15ìë
Ôàðìàêàð
Ïàëåñòèíà
190769abb0f60043248bf1c93d3ae9ce
6251595701030
Íîðìîñîí òàá ï/î 15 ìã N 30 ÐÁ Ôàðìòåõ
cfd446aa0d99161e7f52f0024f671f39
4810183009525
Íóòðèôàéáåð ïîðîøîê 200 ã ñ ìåðí ëîæêîé íà 4.5ã Áàä
Tirupati Lifesciences Private Limited, Èíäèÿ
Èíäèÿ
2e014cd9302806d004ab68c2a986ff83
8901079018281
Îáëåïèõîâîå ìàñëî Àëòàé êàïñ 500ìã N 60 Áàä
92c078a87bceb9755443d4d4a5b4b9f0
4603679006289
Îêîïíèêà ìàñëî 100 ìë Ìàðèñëàâíà ÐÔ
b56f93e09c71f4b42cdefc87aabb5b5c
7930047473976
Îêîïíèêà íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
37f8414d514d513d79a3ac212dbcfacd
Îêîïíèêà ñ öâ êàøòàíà ìàçü 40 ã Ìàðèñëàâíà ÐÔ
e484d69eb4b034aa3cb06e33cdd4488b
7930047474591
Îêóâàéò ôîðòå òàá 0.630 ã N 30 Áàä
Pharmaceutical Company Jelfa SA
bdc5dcf9e1da5ec4660b8e978b4ee566
5904398267029
Îíêîëàí ìàçü ñ àêîíèòîì 40 ã Ìàðèñëàâíà ÐÔ
d6b8ccbea84ed3a958177926b664de11
7930047474683
Îíêîëàí ìàñëî 100 ã Ìàðèñëàâíà ÐÔ
3f4cc3f8b3a2af800c7cb808591a2eac
7930057393080
Îðåõ ÷åðíûé ëèñò 50 ã Ìàðèñëàâíà ÐÔ
0278c14b4c0a9fe21c338e085e3d88f7
7930047476113
Ïàæèòíèê ñåìåíà 50 ã Ìàðèñëàâíà ÐÔ
32bf5e9fa711bbb414921d9d007135d9
7930057391802
Ïåíà-ñïðåé ñ Ä-ïàíòåíîëîì 9% ä/ëèöà è òåëà 90ìë Ìåäèêàëôîðò
ÌåäèêàëÔîðò
bb8617aaf849831c604fddea36e1523e
4815068007498
Ïåíòîâèò Àëòàéâèòàìèíû òàá N 50 Áàä
34e186028e4098aa42a09d9ce171fa92
4603679008061
Ïåïñàí Ð ãåëü ïàê 10 ã N 30
Ðîçà-Ôèòîôàðìà
Ôðàíöèÿ
4a12fcdf963fd7cd418b1882fe6d674a
3760001042078
Ïåðåãîðîäêè ãðåöêîãî îðåõà íàñòîéêà 100 ìë Àëòàé ÐÔ
ee3997e24f6887ad0cc14c3232bd3619
Ïåðåêèñü âîäîðîäà 3% 100 ìë ÐÁ ÁÌÏ
1c9db849efb3fbd1f996c843977cbd09
4813331000023
Ïåðñèêîâîå ìàñëî íåðàô 100 ìë Ìàðèñëàâíà
a7a461ef9bc4cbacae8c54077355ea88
Ïèæìû òðàâà è öâåòû 50 ã Ìàðèñëàâíà ÐÔ
f106ecfa30d0ce591790de561c99b967
7930047476199
Ïëàñò áàêò 6 ñì õ 10 ñì òêàíåâ îñÐÁ
485d21876fc9f8f006d1e864fa6d216a
4812635002535
Ïëàñò Âåðîôàðì áàêò 2.5 ñì õ 7.2 ñì
Âåðîôàðì
329f8cb6c45e272cecc79c189ae881f2
4607083721141
Ïëàñò Âåðîôàðì ïåðö 10 ñì õ 18 ñì ïåðô Äîêòîð Ïåðåö
4e64ad90ec671a8ca4a8662e808fa186
4607083721028
Ïëàñò êàòóø 2 ñì õ 500 ñì òêàí ÐÁ
89940dfbf18187d10a629e8da45c4659
4812635002399
Ïëàñò êàòóø 4 ñì õ 500 ñì ïëåí îñÐÁ
41c16a896bfeb7a4c0e8395ce408c865
4812635001408
Ïëàñò Êîñìîñ âîäîîòòàëê 2ðàçì/óï N 20 Õàðòìàí
Ïàóëü Õàðòìàíí ÀÃ
02edde475712c388c79ea3334f1dac11
4049500472890
Ïëàñò Ñàëèïîä ìîçîë 6 ñì õ 10 ñì
089c84631a95f618631387d63e7b2a47
4607083720953
Ïëàñò Ñèëêîïëàñò N 10 ñòàíäàðò ñòåð áàêò ñîäåðæ ñåðåáðà ïîëèì
Pharmaplast S.A.E.
Åãèïåò
8a534057d7f0329e8ffa67ec7541f6a7
4640018992025
Ïîâÿçêà Êîñìîïîð Å ïëàñò ï/îïåðàö ñòåð 7.2õ5ñì Õàðòìàí
9d24fde9b0e8e447ee046cfdec4f4622
4049500881371
Ïîäîðîæíèêà ëèñò 50 ã Ìàðèñëàâíà ÐÔ
b0e323de5e00fbb24a2bda8335ddd6bb
7930047476236
Ïîäîðîæíèêà ñåìåíà 50 ã Ìàðèñëàâíà ÐÔ
c72c7323baf63f696d42523cd123d0e0
7930047478544
Ïîäîðîæíèêà ñîê 250 ìë Ôèòî-Àïòåêàðü ÐÔ
a651746ca4f7bb220d01b08228aee440
Ïîäñîëíå÷íèê êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
1dc953fefe462e5dab4f304e0370079a
7930047476243
Ïîäñîëíå÷íèê êîðåíü 50 ã Ôèòî-Àïòåêàðü ÐÔ
0ce461cfcfde86ec67f427c3cb27de1e
Ïîëèîêñèäîíèé òàá 12ìã N10
Ïåòðîâàêñ
88c3dc59cd77344e1e4bec0336b39fe1
4607035392023
Ïîëûíè ãîðüêîé òðàâà 50 ã ÐÁ Êàëèíà
Êàëèíà ÎÎÎ/ÐÁ
7c8610edf0a4de149acd35e2aac27a4a
4812843000248
Ïðåãíà-5 êàïñ N 30 Áàä
Êóðòèñ Õåëñ Êàïñ Ñï.ç îî.
c13732b5905326c72c634b690a976b3b
5060461190707
Ïðåçåðâ Êîíòåêñ N 3 êëàññè÷ ñ ãåëåì-ñìàçêîé
ËÐÑ Ïðîäàêòñ Ëòä
4eebb67eb771642ef2ad69563f356523
5060040300145
Ïðîêòî ìàçü ä/ðåêò/íàð ïðèì 20 ã ÐÁ Áîðèñîâ
2f6117a43c73c3c7bea5712cc4284d65
4810201012278
Ïðîïîëèñà íàñòîéêà 100 ìë Ôèòî-Àïòåêàðü ÐÔ
f145dc2f1512962f5e8a210b9a198e44
Ïðîïîëèñíûé ñèðîï ñ ýêñòð/òðàâ 100 ã Ìàðèñëàâíà ÐÔ
8618dcef2e072ed61aef84987fce28ab
7930047470029
Ðàìèëîíã òàá 10 ìã N 30 ÐÁ Ëåêôàðì
281cb72388f1ac204f0832a39a85cdbe
4812608002012
Ðàñòâîð Ìóëüòèâåéâ ñòàíäàðò 100 ìë á/êîíò ÐÁ
×èñòàÿ ðåêà ÎÎÎ
c174290649f246d16e35a47ef54b0634
4814052000118
Ðàñòîðîïøè ìàñëî 100 ìë Ìàðèñëàâíà ÐÔ
6c73a4eeeae1286a1f0f98bb4bb5c106
7930047478087
Ðàñòîðîïøè ìàñëî êàïñ 300 ìã N 100 ÐÔ ÁÀÄ ÐåàëÊàïñ
46d551461be8a4ac88a0ca3f92d340d6
4607136741034
Ðîäèîëà ðîçîâàÿ Çîëîòîé êîðåíü 25 ã Ôèòî-Àïòåêàðü ÐÔ
3b01fe4d4a367066a9bb7b6cc1ff4463
Ðîäèîëà ðîçîâàÿ Çîëîòîé êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
1cca08022d619261e1ce3f7a8b572f15
7930047476328
Ðîäèîëà ðîçîâàÿ Çîëîòîé êîðåíü â áàíêå 100ã Ôèòî-Àïòåêàðü ÐÔ
061d401f165a736ff967106707258681
Ðîçìàðèí ëåêàðñòâ òðàâà 50 ã Ìàðèñëàâíà ÐÔ
ecc01bafdbebafcee1f8ad412e33af0b
7930047476342
Ðîçóâàñòàòèí òàá ï/î  5 ìã N 30 ÐÁ Ëåêôàðì
95afb54491561b0b415ca067e2e27053
4812608006546
Ðîçóëèï ïëþñ êàïñ 10ìã/10ìã N 30
0876c82eeeddbb83319e9f1e77100cc9
5995327156439
Ðîìàøêè àïòå÷í öâåòû 50 ã Ìàðèñëàâíà ÐÔ
77e6fb638d5fa65e88ac1f4f2aa2826c
7930047476359
Ðîìàøêè öâåòêè öåëüí 40 ã ÐÁ Áèîòåñò
61199031827726cf91dede89cf2868d7
4810363002407
Ðîòàòèò ýêñòð æèäêèé ä/ìåñòí ïðèì ôë 50ìë ÐÁ Ôåðåéí
Ôåðåéí
8a3c7b9c979c26cc01332dd22d1b627b
4814405001496
Ðÿáèíà ÷åðíîïëîäíàÿ 50 ã Ôèòî-Àïòåêàðü ÐÔ
dad53ac75a5e004dc32ab7c60814e3d0
Ñàáåëüíèê áîëîòíûé íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
f8d5e6d3b56b0b71907a3c7cd843d70d
Ñàãàí-äàéëÿ ëèñò è öâåòû/ðîäîäåíäðîí Àäàìñà/ 50 ã Ìàðèñëàâíà ÐÔ
3a1af7eceab179be18183f9840bae479
7930057391031
Ñáîð N110 Ïðè àðòðèòå è àðòðîçå 200 ã Ìàðèñëàâíà ÐÔ
8d482de00943367cd4f08b62ab48f820
7930047476892
Ñáîð N111 Ïðè îñòåîõîíäðîçå è ìåæïîç. ãðûæàõ 200 ã Ìàðèñëàâíà ÐÔ
2310f65c846a9a9508a248cda365ffb3
7930047471668
Ñáîð N13 Ïðè êðîâîòå÷åí,îáèëüí/ìåíñòðóàöèÿõ 200 ã Ìàðèñëàâíà ÐÔ
efc4cdcee4511db9e709ced0be0509c2
7930047472788
Ñáîð N135 Ïðè âåãåòîñîñóäèñòîé äèñòîíèè 200 ã Ìàðèñëàâíà ÐÔ
21901311b5b6e17179e97cbb3ab981f0
Ñáîð N139 Ïðè ãèïåðòîíèè 200 ã Ìàðèñëàâíà ÐÔ
39d29845404b261649520b5163df5fcf
7930047471231
Ñáîð N15 Ïðè ìèîìå ìàòêè 200 ã Ìàðèñëàâíà ÐÔ
05bb297dd2accbf34b178a1bc610b696
7930047472702
Ñáîð N17 Ïðè Ôèáðîàäåíîìå ìîëî÷íîé æåëåçû 200 ã Ìàðèñëàâíà ÐÔ
f6aacd6c478c9961b00504aa4cd27176
7930047472306
Ñáîð N20 Ðàññàñûâàþùèé ñïàéêè 200 ã Ìàðèñëàâíà ÐÔ
04e4224d52fbb0a6bd07cc483019b04e
7930047472986
Ñáîð N33 Äëÿ î÷èùåíèÿ ëèìôû êðîâè 200 ã Ìàðèñëàâíà ÐÔ
8faec10ce170af6e610b7bbca87a71c7
7930047472146
Ñáîð N37 Äëÿ ïîõóäåíèÿ 200 ã Ìàðèñëàâíà ÐÔ
2e30b6fe1bb29d51eccee25202577161
7930047471569
Ñáîð N39 Ïðîòèâîàëêîãîëüíûé 200 ã Ìàðèñëàâíà ÐÔ
fc0c632e91e10e605dce3efc0a146dc2
7930047473020
Ñáîð N40 Ïðîòèâîïàðàçèòàðíûé 200 ã Ìàðèñëàâíà ÐÔ
f44961bfbb68ff95cea228f22e569aaa
7930047471132
Ñáîð N42 Ãðóäíîé 200 ã Ìàðèñëàâíà ÐÔ
1309bb73075f3666693bf843ff4e1b1a
7930047471965
Ñáîð N47 Ïðè íàñìîðê/ãàéìîðèò/àäåíîèäàõ 100 ã Ìàðèñëàâíà ÐÔ
666776cf4d5903967058404fe78f8e73
7930047473792
Ñáîð N62 Ïðè êîëèòå(ÍßÊ,áîëåçíè Êðîíà) 100 ã Ìàðèñëàâíà ÐÔ
9f716942d4ebe062794871fa373dbb4a
7930047473686
Ñáîð N70 Ïðè ãëîìåðóëîíåôðèòå è ïî÷.íåäîñòàòî÷íîñòè 100 ã Ìàðèñëàâíà ÐÔ
385f4676258483c8ed57562ad20c2c8a
7930047477776
Ñáîð N71 Ïðè êàìíÿõ â ïî÷êàõ è ìî÷åâîì 200 ã Ìàðèñëàâíà ÐÔ
69b468b373860a3f6bae91a943c8b77d
7930047471316
Ñáîð N78 Ïðè áîëåçíè Ïàðêèíñîíà 100 ã Ìàðèñëàâíà ÐÔ
6cfd37ee649e130655b0af3a5f4f88aa
7930047477622
Ñáîð äåòñêèé Ïðîòèâîèíôåêöèîííûé 100 ã Ìàðèñëàâíà ÐÔ
8b78062c424e7d760aa1a963af8b3dad
7930047471552
Ñáîð Ïðîòèâîïàðàçèòàðíûé 200 ã Ôèòî-Àïòåêàðü ÐÔ
6bb2c74dc04de733ffa739434ee33339
Ñâå÷è N15 Ãèíåêîëîã ñ æèâèöåé N 10 Ìàðèñëàâíà ÐÔ
91d5ed5d23a019b2acf7792f8561d66c
7930047477981
Ñâå÷è N4 Ïðè áåñïëîäèè N10 Ìàðèñëàâíà ÐÔ
c2e671d3c72738cc7f02b633be4a0447
7930047477875
Ñâå÷è N6 Ïðè ãåìîððîå N 10 Ìàðèñëàâíà ÐÔ
245c023d1af8e38ee08b2f1602da1e05
7930047477899
Ñâå÷è N7 Ïðè ãèíåê/öèñòèòå N 10 Ìàðèñëàâíà ÐÔ
a88d835f4fe3bc785b4c28dd7b47938a
7930047477905
Ñâå÷è N8 Ïðè ïîëèïàõ è êèñòàõ â êèøå÷íèêå,íà ïî÷êàõ,ïå÷åíè N 10 Ìàðèñëàâíà ÐÔ
8656fce8806eaa1e3cc07a7f4ecb2653
7930047477912
Ñåïòîëåòå Òîòàë òàá ä/ðàñ 3ìã/1ìã N 16 ëèìîí/ìåä
8eb0aa9e88461f3d65d619fd9a09d23a
3838989698799
Ñåïòîìèðèí ð-ð 0.01% 100 ìë ÐÁ ÁÌÏ
aab487a80297287a1ec34cdb22040555
4810133004730
Ñåðäå÷íûå êàïëè íàñòîéêà 50 ìë ÐÁ Ôåðåéí
ecce9cc82b015656dae7ee99d4387927
4814405001618
Ñèíàô ìàçü 0.25 % 15 ã ÐÁ Áîðèñ
6149e32e5b6f1f0720dcd908a96fcd9b
4810201007939
Ñèíóïðåò ýêñòðàêò òàá 160 ìã N 20
Ðîòòåíäîðô ôàðìà
faae5238a6d7f0ac0f7146c7e5645b75
4029799168001
Ñèð Ïîëåñüå6 Øèïîâíèê íà ôðóêòîçå 250 ìë ÐÁ Áàä Ýêçîí
Ýêçîí, ÐÁ
df11104e53d9279d7dedb7b30c65b01f
4810155000710
Ñêèí-êàï êðåì 50ã
Chemigroup France
523da841354d6fee30876266f26d9a10
8470000639586
Ñîëîäêà êîðåíü 50 ã Ìàðèñëàâíà ÐÔ
99c00900e33c6e93fa543501066dbf43
7930047476434
Ñîñíû ïûëüöà (ïîðîøîê) 30 ã Ìàðèñëàâíà ÐÔ
a3514cba767516726c46d6c6e1a7b9ca
7930057393035
Ñîôîðà ÿïîíñê ïëîäû 50 ã Ìàðèñëàâíà ÐÔ
dbe777e114a354288ae9f7df65f77ea4
7930047476489
Ñîôîðû ÿïîíñêîé íàñòîéêà 100 ìë Ôèòî-Àïòåêàðü ÐÔ
561d0619a69008aa1de4a78b4ae53cce
Ñïðèíöîâêà N 15 òèï À
Ôîðàíñ
bba35c367fc68ecde9ad5941794431b4
4742225002327
Ñòîï-ìåòàñòàçû íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
39f4604b41bbb437caff7053b1ca3ed9
Ñòîï-ìåòàñòàçû ñáîð 200 ã Ôèòî-Àïòåêàðü ÐÔ
ea23b44e5301776078f16d9a69f3a989
Ñòðåïòîöèä 2 ã N5 ÐÔ
ÎÎÎ ÒÅÕÍÎÏÀÐÊ-ÖÅÍÒÐ
ad8b6aa1dcaa6a572af21d929b9f3522
4602813000794
Ñóäîðîãèíóì òàá N56 Áàä
Ä-ð Òàéññ
63ece86af81923c5f78b8d77b0a458f9
4016369741139
Ñóïõåðá Êîëëàãåí êîìïëåêñ òàá 1340ìã N 30 Áàä
Àìáðîçèÿ Ñóïõåðá Ëòä Èçðàèëü
Èçðàèëü
da66762bc654fee8304535074f194fde
7290017243917
Ñóïõåðá Ìàãíèÿ öèòðàò+âèò Â6 òàá 1120 ìã N 30 Áàä
38fb31c81c47509ab25b5cf4c9e63733
7290014545557
Ñóðåïêà òðàâà 50 ã Ôèòî-Àïòåêàðü ÐÔ
63aa4ba8d3e92a358143982801f3f580
Òàòàðíèê êîëþ÷èé òðàâà 25 ã Ôèòî-Àïòåêàðü ÐÔ
086cbe395f9433404815d9ae1028c1c0
Òåðàôëåêñ õîíäðîêðåì ôîðòå 30 ã
Íèæôàðì
177f43b9a46b19fe127462ce522729de
4250369507559
Òåñò ä/îïðåä áåðåì Ìàìà-òåñò(10 ìÌÅ/ìë) 1 òåñò-ïîëîñêà
Áåðîìåä ÃìáÕ
078d7ca76e8f1c5c3c1e6c09e2168013
4032731504768
Òîáðåêñ ãë. êàïëè 0.3% 5 ìë
59a5de18a3e44aaf9cd483043925e943
7612797402887
Òîïîëÿ ÷åðíîãî ïî÷êè íàñòîéêà 100 ìë Àëòàé ÐÔ
5a3948d01fe04f77a97058a43fe791e7
Òðàéêîð òàá 145 ìã N 30
Ôóðíüå Ëàáîðàòîðèç
Èðëàíäèÿ
b42256fe352da1071491ca9aba598bf5
8002660024848
Òðèïòîôàí Ô-ëà ñïîêîéñòâèÿ êàï N 60 Áàä Ýâàëàð
d4cfddc6c5735bc1e8642a5aaf2e8f82
4602242021391
Òûñÿ÷åëèñòíèêà òðàâà 50 ã ÐÁ Áèîòåñò
2ec7413b3b00ad3f7e7d99471525fe76
4810363001493
Óãîëü àêòèâèðîâàííûé 250 ìã N 30 ÐÁ Ýêçîí
7bff7d4deca94a7cf85f071b5f7e2af8
4810155003209
Óïñàðèí ÓÏÑÀ òàá 500 ìã N 16
ÓÏÑÀ
d7efd35227a2fd7e1fc0aadf37622e29
3585553245766
Óðñàêëèí êàïñ 250 ìã N 60 ÐÁ Àêàäåìôàðì
Àêàäåìôàðì ÈÁÔ ÍÀÍ, ÐÁ
2fb5035b1ea4f54d3a9d5637415b7cb7
4814279001004
Óñïîêîèòåëüíûå êàïëè 50 ìë ÐÁ Áîðèñ
6265a693437d0eff87695f4ff1922a59
4810201009346
Ôàìîòèäèí òàá 40 ìã N 20 ÐÁ Áîðèñ
c4aeb00c7e84b2c5a54f3a34b47bbde2
4810201018171
Ôåìèáèîí II òàá ï/î N 28+êàïñ ìÿãê N 28 Áàä
P&G Health Austria GmbH
f9be902d8847f76d36028fb2a45184ae
8006540222478
Ôèòîëàêñ òàá 500 ìã N 100 Áàä Ýâàëàð
72546f9b684764cdfbe4008a3a661325
4602242025238
Ôèòî÷àé Äðóã Âàøèõ ïî÷åê ô/ï 1.5ã N 20 Áàä ÐÔ Öåëåáíàÿ ïîëÿíà
Ôèòîôàðì ÏÊÔ,Ðîññèÿ
6e790f5bf36ea6bd48a9640a40efc7e5
4603762009999
Ôèòî÷àé Ýâàëàð Î÷àíêà 50 ã Áàä
e9b99fadc4723f6987e2dca3318a36fc
4602242001416
Ôóðàñîë ïîð ä/ïðèã ð-ðà 100 ìã N 5
07736b767456f60e7c974d677b910882
4750258316564
Ôóðàöèëèí òàá 20 ìã N 10
8cff5f1ca22e7bfc84b9ae4e4b50b632
4604060016115
Õëîðãåêñèäèíà áèãëþê 0.05% 100ìë ÐÁ ÁÌÏ
ae9adec6362725dfe4c86af139da23ce
4813331000047
Õëîðãåêñèäèíà áèãëþêîíàò 0.05% 200ìë ñð-âî äåç Ðô Ñàìàðà
ÎÎÎ Ñàìàðñêàÿ ôàðìàöåâòè÷åñêàÿ ôàáðèêà
2182265a1f83c62c582ce14826811299
4607001500742
Õëîðîïèðàìèí êðåì íàðóæ 10ìã/ã 18 ã ÐÁ Áîðèñ
43f23e7121e6e412f70dcc2870a61946
4810201013695
Õëîðîïèðàìèí òàá 25 ìã N 20 ÐÁ Ëåêôàðì
Ëåêôàðì, ÐÁ
efaa46e754637918afa7f81fa56a46c3
4812608009646
Öåòðèí òàá 10 ìã N 20 ÐÁ Áîðèñ
Ä-ð Ðåääèñ Ëàá. Ëòä, Èíäèÿ óïàêîâàíî ÎÀÎ Áîðèñîâñ
0f49cdd8fc7b9b3f913041cdce5b6d5d
4810201019802
Öèêëàìåíà êàïëè 20 ìë Ìàðèñëàâíà ÐÔ
752907aaa5cd8f59747f1d516f693d7d
7930047473952
Öèêîðèé îáûê êîðåíü 50 ã Áàä Íàñëåäèå ïðèðîäû
Êàìåëèÿ
b2eecbab08633f6ca21d46327a0aea3f
4630000893454
×àãà áåðåçîâàÿ ô/ï 2.0 N30 Ìàðèñëàâíà ÐÔ
023ea475dd0ca351827418689a5080f1
7930057393134
×àãà öåëüí.êóñî÷êè 50 ã Ôèòî-Àïòåêàðü ÐÔ
c7bddf176aebd4120af93258cbc4f645
×àé Ïîõóäåé çåë ÿáëîêî ô/ï 2.0 N30 Áàä
Öýðåðà ÒÄ
ba2102664e09331ee666477f0ce95da1
4607020641983
×àéíûé íàïèòîê Æåëóäî÷íûé ô/ï 2.0 N30 Ìàðèñëàâíà ÐÔ
97c4c46980a97433a1b72f6fdd257045
7930057390034
×àéíûé íàïèòîê Çîðêîñòü ô/ï 2.0 N30 Ìàðèñëàâíà ÐÔ
a774897dcfd6148486ce5d7d622979b8
7930057390249
×àéíûé íàïèòîê Ñåêðåò êðàñîòû ô/ï 2.0 N30 Ìàðèñëàâíà ÐÔ
726283f3fb1595728b9d82ed2c5e5ba6
7930057390188
×àéíûé íàïèòîê Ñóñòàâíûé ô/ï 2.0 N30 Ìàðèñëàâíà ÐÔ
9de105a6bb0e6add20a5ab97375a4772
7930057390058
×åðíèêà ëèñò 50 ã Ìàðèñëàâíà ÐÔ
0552ff27832101364dcb5a0f5d012748
7930047476694
×åðíèêà ïîáåãè 50 ã Ôèòî-Àïòåêàðü ÐÔ
61ed3854d553e1e03104d7c17a947805
×åðíèêà ôèòî÷àé 50 ã Áàä ÐÔ Õîðñò
42d0a9994022344ffab0c47a9f17e16f
4680002550800
×èñòîòåëà íàñòîéêà 100 ìë Ôèòî-Àïòåêàðü ÐÔ
0f113de2a36bf4a5ed40cd319064d502
Øàëôåé òàá äëÿ ðàññ N 30 ÐÁ Ðóáèê
16930d876fea4855fd147e10bf61fb46
4810243005139
Øèèòàêå ãðèá íàñòîéêà 250 ìë Ôèòî-Àïòåêàðü ÐÔ
6d7c749c2548ac0f1c7d30ebd8d57c08
Øïðèö  5ìë 2êîìï Ëóåð ÐÁ
Ìåäïëàñò ÎÀÎ ÐÁ
62c07f592d1fbc22f6678f416ba4f6b6
4811224000013
Ýêñòðàêò ñîëîäêè Ïëþñ òàá N 30 Áàä
ÊÂÀÄÐÀÒ Ñ
d0dd2f711eb7f7058637647cf423f774
4660011217284
Ýëåâèò âòîðîé è òðåéòèé òðèìåñòð êàïñ 1279.1ìã N 30 Áàä
Áåðëèìåä Ñ.À.
a5e7d8111fd7251df214f047c356877c
4250369508167
ßêîðöû ñòåëþùèåñÿ íàñòîéêà 100 ìë Ôèòî-Àïòåêàðü ÐÔ
e6e81ac4204cb8706f0ae922fb680ffa
ßðóòêà òðàâà 50 ã Ìàðèñëàâíà ÐÔ
1b051841857abbec2bd0108a2cd58bd6
7930047476755
ßðóòêà òðàâà 50 ã Ôèòî-Àïòåêàðü ÐÔ
25d9a62115ea8b4e4a68226b3fcf6b0e